Healthcare

The approval was built on data from the Phase 3 VALOR program, which evaluated brepocitinib's efficacy and safety in the DM patient population as part of Pfizer's broader clinical development effort in immunology and inflammation.

Launching a patient- and caregiver-facing information portal ahead of program initiation is a common step for rare pediatric disease developers, given the small and geographically dispersed patient populations typical of ultra-rare conditions, where early outreach can meaningfully affect enrollment timelines once a study opens.

YCANTH is a proprietary formulation of cantharidin, a compound with a long history of use in wart and molluscum treatment, delivered through Verrica's applicator technology (VP-102).

Spikevax and mNEXSPIKE represent Moderna's (NASDAQ:MRNA) core respiratoryVaccinefranchise, and annual approval of updated formulas is a recurring regulatory event for the company, similar in structure to the seasonal update process used for influenza vaccines.

A 2032Maturityplaces the notes on a roughly seven-to-eight-year horizon from issuance, positioning the raise as a long-termCapital Structuredecision rather than a near-termLiquiditymeasure.

Because the dataset reflects only six evaluable patients at this stage, the percentages represent a small early sample rather than a statistically powered result — five of six patients responding would itself produce an 83% ORR — but the consistency of benefit across the …

Hypoparathyroidism is often managed with calcium and active vitamin D supplementation, an approach that can require frequent monitoring and does not always adequately control symptoms, leaving room for hormone-replacement approaches like canvuparatide that aim to more directly address the underlying deficiency.